what is glp-1 drugs for weight loss from the Gray Market What to Make of the

AASLD guidance recommends considering them in patients with concurrent co-morbidities such as obesity and diabetes given their potential benefit in NAFLD

FDA-approved for chronic weight management

Orphanet Journal of Rare Diseases

FDA labeling for EGRIFTA WR states that tesamorelin is indicated for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, while also noting that it is not indicated for weight-loss management and that long-term cardiovascular safety has not been established. For a research comparison article, Tesamorelin gives useful context: it shows that the GHRH analog category is not limited to CJC-1295 and Sermorelin